 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 625 | 回復: 2 | |||
| 當前只顯示滿足指定條件的回帖，點擊這里查看本話題的所有回帖 | |||
yuanbing000新蟲 (小有名氣)
|
[交流]
(轉(zhuǎn)）20160302 ECA新聞：中國和印度原料藥生產(chǎn)商欺詐和主要GMP違規(guī) 已有1人參與
|
||
| (轉(zhuǎn)）20160302 ECA新聞：中國和印度原料藥生產(chǎn)商欺詐和主要GMP違規(guī) |
回復此樓» 本帖附件資源列表
-
歡迎監(jiān)督和反饋：小木蟲僅提供交流平臺，不對該內(nèi)容負責。
本內(nèi)容由用戶自主發(fā)布，如果其內(nèi)容涉及到知識產(chǎn)權(quán)問題，其責任在于用戶本人，如對版權(quán)有異議，請聯(lián)系郵箱：xiaomuchong@tal.com - 附件 1 : (轉(zhuǎn)）20160302_ECA新聞：中國和印度原料藥生產(chǎn)商欺詐和主要GMP違規(guī)__.docx
2016-03-03 08:26:51, 17.77 K
» 猜你喜歡
SPguide®：小鼠體內(nèi)脾臟轉(zhuǎn)染的一鍵解決方案
已經(jīng)有0人回復
-
高效肺靶向RNA轉(zhuǎn)染，加速肺部RNA藥物開發(fā)
已經(jīng)有2人回復
-
藥物學論文潤色/翻譯怎么收費?
已經(jīng)有201人回復
-
二糖的糖脂，合成后sephadex LH-20分離不出來，求助
已經(jīng)有1人回復
-
南方醫(yī)科大學珠江醫(yī)院肖計生課題組招收博士生 （2026年入學）
已經(jīng)有2人回復
-
349藥學專碩105500求調(diào)劑
已經(jīng)有0人回復
-
求調(diào)劑
已經(jīng)有1人回復
-
298求調(diào)劑一志愿中海洋
已經(jīng)有3人回復
-
藥學調(diào)劑申請自薦信，一志愿中南大學
已經(jīng)有1人回復
-
藥學349專碩求調(diào)劑
已經(jīng)有1人回復
-
《左乙拉西坦注射液制備工藝研究、質(zhì)量控制和穩(wěn)定性研究》下載
已經(jīng)有1人回復
shidongke
金蟲 (著名寫手)
- 應助: 26 (小學生)
- 金幣: 2275.2
- 散金: 91
- 紅花: 24
- 帖子: 1888
- 在線: 325.1小時
- 蟲號: 636886
- 注冊: 2008-10-26
- 性別: GG
- 專業(yè): 有機合成
|
20160302 ECA新聞：中國和印度原料藥生產(chǎn)商欺詐和主要GMP違規(guī) GMP News 02/03/2016 Fraud and Major GMP Violations at API Manufacturers in India and China 中國和印度原料藥生產(chǎn)商欺詐和主要GMP違規(guī) The Non-Compliance reports in the Eudra-GMDP database of the European Medicines Agency (EMA)are - to a certain extent - the European counterpart of FDA's Warning Letters. These reports are first drawn up then put in the database after a GMP inspection performed by a representative of the European national competent authorities at an API or medicinal product manufacturer showed serious GMP deficiencies. Similar to Warning Letters, the consequences of Non-Compliance reports are for the companies concerned critical, e.g. withdrawal of the GMP certificate or product recalls. EMA的歐盟GMDP數(shù)據(jù)庫里的不符合報告是----某種程度上----歐洲版的FDA警告信。這些報告在歐洲國家藥監(jiān)局對原料藥或制劑生產(chǎn)商的GMP檢查中發(fā)現(xiàn)嚴重GMP缺陷后先寫就，然后放進數(shù)據(jù)庫。與警告信相似，不符合報告的對于公司來說是關鍵的，例如，吊銷GMP證書或召回產(chǎn)品。 Two Non-Compliance reports issued at the end of last year concerned API production sites in China and India. 中國和印度有2份不符合報告在去年年底公布。 Regarding the Chinese manufacturer "Minsheng Group Shaoxing Pharmaceutical Co. Ltd", GMP inspectors from the French competent authority found 2 critical and 4 "major" deficiencies. Those deficiencies are summarised below: 關于中國的生產(chǎn)商“民生集團紹興藥業(yè)有限公司”，來自法國藥監(jiān)的GMP檢查員發(fā)現(xiàn)2個關鍵4個主要缺陷。這些缺陷總結(jié)如下： • Falsification of source of starting materials: the starting materials supposed to have been manufactured in-house actually came from an external non GMP-compliant supplier and have been repackaged and relabelled accordingly (critical deficiency). • 原料藥來源做假：起始物料應該是公司內(nèi)部自己生產(chǎn)的，而實際是來自外部非GMP符合的供應商，并且進行了相應的重新包裝和重新標簽（關鍵缺陷） • The API manufactured according to the Chinese Pharmacopoeia was wrongly and intentionally released as USP quality; there was no traceability of the testing activities (critical deficiency). • 根據(jù)中國藥典生產(chǎn)的原料藥錯誤地有意作為USP質(zhì)量放行，沒有檢測活動可供追溯。（關鍵缺陷） • The cleaning and maintenance operations of the manufacturing line were insufficient (major). • 生產(chǎn)線的清潔和維護不充分（主要缺陷） • Deficient equipment design (pipelines); non-compliant transfer of the intermediate solution using nitrogen; non-compliant change management with regard to equipment (major). • 設備設計有缺陷（管線）、中間體溶液使用氮氣傳送不合規(guī)、設備變更管理不合規(guī)（主要缺陷） • Hoses were lying on a dirty floor of an area not mentioned in the general layout of the site. Those hoses were unidentified and their cleaning status was unclear (major). • 軟管放在臟的地面上，該區(qū)域在工廠總平圖上沒有提到。這些軟管沒有標識，其清潔狀態(tài)不清楚（主要缺陷） • Audit trail function in the chromatographic system was deactivated; there was no procedure in place for audit trail (major). • 色譜系統(tǒng)的審計追蹤功能沒有激活，沒有審計追蹤程序（主要缺陷） By the way, the inspection of the Chinese manufacturer performed by the French authority was part of the prequalification programme of the WHO which means that it had been initiated by the manufacturer himself within the framework of his application for the inclusion of his products in the list of prequalified pharmaceutical APIs of the WHO. 順便說一下，法國藥監(jiān)對中國生產(chǎn)商的檢查是WHO預確認程序的一部分，這表示該檢查是由生產(chǎn)商自己激活的，意在將其產(chǎn)品包括在WHO的預確認原料藥清單上。 Secondly, the inspection of the Indian company "AstraZeneca Pharma India Ltd." was carried our by inspectors of the Swedish competent authority. The GMP deviations observed are summarised below: 第二個是由瑞典藥監(jiān)對印度公司“阿斯利康藥業(yè)印度公司”的檢查。發(fā)現(xiàn)的GMP偏差總結(jié)如下： • The manufacturing process of the API was not sufficiently validated (major). • 原料藥生產(chǎn)工藝未經(jīng)過充分驗證（主要缺陷） • The documentation routine was not GMP-compliant (major). • 文件記錄常規(guī)做法不合規(guī)（主要缺陷） • Data integrity wasn't assured (major). • 未保證數(shù)據(jù)完整性（主要缺陷） • Design and maintenance of the equipment was insufficient (major). • 設備的設計和維護不充分（主要缺陷） The GMP deficiencies discovered in both production sites concern essential GMP requirements for the manufacture of APIs as laid down in the ICH Q7 Guideline and in the EG GMP Guide Part II since already 16 years. Unfortunately, GMP inspectors from European authorities, the EDQM and the FDA are - again and again - confronted to such GMP deficiencies, mainly in Indian and Chinese manufacturing sites. 在兩個生產(chǎn)工廠里發(fā)現(xiàn)的GMP缺陷關系到基本的GMP要求，是ICH Q7指南和EU GMP指南第二部分16年之前就制訂的原料藥生產(chǎn)要求。不幸的是，歐洲藥監(jiān)GMP檢查員，EDQM和FDA一而再，再而三地面對這樣的GMP缺陷，主要是在印度和中國生產(chǎn)工廠。 |
3樓2016-08-24 10:55:33
shidongke
金蟲 (著名寫手)
- 應助: 26 (小學生)
- 金幣: 2275.2
- 散金: 91
- 紅花: 24
- 帖子: 1888
- 在線: 325.1小時
- 蟲號: 636886
- 注冊: 2008-10-26
- 性別: GG
- 專業(yè): 有機合成
2樓2016-08-24 10:55:08
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 347求調(diào)劑 +3 | 山頂見α 2026-03-25 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 材料277求調(diào)劑 +7 | min3 2026-03-24 | 7/350 |
|
|
|
[考研] 求調(diào)劑推薦 材料 304 +15 | 荷包蛋hyj 2026-03-26 | 15/750 |
|
|
|
[考研] 086000調(diào)劑 +3 | 7901117076 2026-03-26 | 3/150 |
|
|
|
[考博] 26申博 +3 | 加油沖��！ 2026-03-26 | 3/150 |
|
|
|
[考研] 安徽大學專碩生物與醫(yī)藥專業(yè)(086000)324分，英語已過四六級，六級521，求調(diào)劑 +4 | 美味可樂雞翅 2026-03-26 | 4/200 |
|
|
|
[考研] 305求調(diào)劑 +5 | 哇盧卡庫 2026-03-26 | 5/250 |
|
|
|
[考研] 322求調(diào)劑 +4 | 我真的很想學習 2026-03-23 | 4/200 |
|
|
|
[考研] 考研調(diào)劑 +10 | 呼呼？~+123456 2026-03-24 | 10/500 |
|
|
|
[考研] 一志愿陜師大生物學071000，298分，求調(diào)劑 +5 | SYA！ 2026-03-23 | 5/250 |
|
|
|
[考研] 081200-11408-276學碩求調(diào)劑 +4 | 崔wj 2026-03-26 | 4/200 |
|
|
|
[碩博家園] 招收生物學/細胞生物學調(diào)劑 +3 | IceGuo 2026-03-26 | 4/200 |
|
|
|
[考研] 求調(diào)劑 一志愿 本科 北科大 化學 343 +6 | 13831862839 2026-03-24 | 7/350 |
|
|
|
[考研] 081200-11408-276學碩求調(diào)劑 +3 | 崔wj 2026-03-26 | 3/150 |
|
|
|
[考研] 281求調(diào)劑 +3 | 亞克西good 2026-03-26 | 5/250 |
|
|
|
[考研] 機械學碩總分317求調(diào)劑�。。�！ +4 | Acaciad 2026-03-25 | 4/200 |
|
|
|
[考研] 求b區(qū)院校調(diào)劑 +4 | 周56 2026-03-24 | 5/250 |
|
|
|
[考研] 285求調(diào)劑 +3 | AZMK 2026-03-24 | 3/150 |
|
|
|
[考研] 384求調(diào)劑 +3 | 子系博 2026-03-22 | 6/300 |
|
|
|
[考研] 求老師收我 +3 | zzh16938784 2026-03-23 | 3/150 |
|